Kala Pharmaceuticals: Q1 Earnings Insights

 

Shares of Kala Pharmaceuticals KALA fell 0.5% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 9.26% over the past year to ($0.49), which beat the estimate of ($0.68).

Revenue of $3,266,000 higher by 204.95% from the same period last year, which missed the estimate of $4,180,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 05, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/yu62x3fd

Recent Stock Performance

Company's 52-week high was at $14.68

52-week low: $6.00

Price action over last quarter: down 13.36%

Company Description

Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!